MHC molecules, especially human leukocyte antigen class I (HLA-I) alleles, play a critical role in anticancer immunity by recognizing tumor-specific antigens, and their heterozygosity influences patient survival after ICIs treatments (52). Here, HLA-C is linked to neoplasm.